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Abstract: Antibiotic discovery is vital when considering the increasing antimicrobial resistance threat.
The aim of this work was to provide a high-throughput screen (HTS) assay using multidrug-resistant
Escherichia coli strains to enable further research into antimicrobial lead discovery and identify novel
antimicrobials. This study describes a primary HTS of a diverse library of 7884 small molecules
against a susceptible E. coli strain. A secondary screening of 112 molecules against four E. coli strains
with different susceptibility profiles revealed NSC319726 as a potential antimicrobial lead serving as
a novel template. NSC319726 is a good candidate for an analoguing program.
Keywords: sulfonamide resistance; antifolate; Escherichia coli; antimicrobial lead; drug discovery;
multidrug resistance
1. Introduction
Recently, multidrug-resistant bacteria have emerged, threatening human health at a global level [1].
Considering this threat, it is vital to identify novel antimicrobial classes [2–4]. Nonetheless, investments
in antimicrobial lead discovery [5] and the number of approved novel antimicrobials are on the
decline [3,4,6,7]. Despite discovery efforts towards mechanistic-based high-throughput screening
(HTS) [8], the pharmaceutical industry has mostly abandoned the anti-infective arena because of its
limited financial attractiveness, the scientific challenges inherent to antibiotic drug discovery, and the
complex regulatory framework [5]. A number of measures (collaborative programs, new funds,
regulatory measures, etc.) have been launched in the past years aiming to revive the antimicrobial
pipeline and to overcome bottlenecks in the development of new antibiotics. However, these initiatives
still fall short of providing all the necessary tools to cope with the magnitude of the public health
challenges faced today. Filling the antimicrobial drug discovery pipeline has never been as challenging
as now, with the currently used scaffolds and protein targets being overexploited. The identification
of a novel anti-infective lead can be achieved by revitalizing old antimicrobial targets with new
inhibitors or by identifying new antimicrobial targets. New inhibitors can be molecularly tailored
old scaffolds, new scaffolds, or repurposed compounds. Folate biosynthesis is a well-established
antimicrobial target validated by the use of clinically effective sulfonamides and trimethoprim (TMP).
The ongoing effort to identify novel antifolates is stimulated by the central biological importance of
folates and the absence of its biosynthetic pathway in eukaryotes [9]. Previous antifolate discovery
efforts have focused on the folic acid pathway as the primary metabolism to folates, specifically on
the dihydropteroate synthase and the dihydrofolate reductase enzymes within the folic acid pathway.
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However, unexplored molecular targets remain in earlier steps of the folate synthesis, such as within
the chorismate and shikimate pathways. In an attempt to identify novel antifolate leads effective
against multidrug-resistant strains, a novel whole cell HTS assay specific to the chorismate pathway
was developed.
2. Materials and Methods
2.1. Bacterial Isolates
Three Escherichia coli American Type Culture Collection (ATCC) strains 25922, 86980, and 29181
were used in this study along with the clinical isolate E. coli AHDRCC 81113. In order to
identify antifolate leads effective against resistant strains, the tested strains used in the assay had
different susceptibly profiles towards sulfamethoxazole (SMX), trimethoprim/sulfamethoxazole
(SXT), and TMP (Sigma-Aldrich, St. Louis, MO, USA). The tested resistant strains were also
resistant to antimicrobials other than antifolates (including ampicillin, florfenicol, kanamycin,
penicillin, streptomycin, and tilmicosin). Escherichia coli ATCC 25922 was susceptible to SMX,
SXT (concentration ratio 1:19), and TMP and was a Clinical and Laboratory Standards Institute
(CLSI)-recommended quality control strain for susceptibility testing of potentiated sulfonamides and
other antimicrobials [10,11]. E. coli ATCC 86980 contained the pLS88 plasmid conferring resistance
to kanamycin, streptomycin, and sulfonamide. E. coli ATCC 29181 was an ATCC strain resistant
to streptomycin and TMP. E. coli AHDRCC 81113 was a clinical isolate from the Zoetis culture
collection (E. coli AHDRCC 81113, collected in 2014 from cattle from Ontario, Canada) that is
resistant to ampicillin, florfenicol, penicillin, SMX, SXT (1:19), tilmicosin, and TMP. Susceptibility
profiles to NSC319726 (Cayman Chemical, Ann Arbor, MI, USA), SMX, SXT (1:19) and TMP were
confirmed with minimum inhibitory concentration (MIC) testing (n = 2) by the broth microdilution
procedure as described by the CLSI document Vet01-A4 [10]. Quality control was conducted using
CLSI-recommended quality control strains and antimicrobials. Quality control strains used were
Enterococcus faecalis ATCC 29212, Staphylococcus aureus ATCC 29213, and E. coli ATCC 25922. Quality
control antimicrobials used were ampicillin, amoxicillin/clavulanic acid combination (2:1, v:v), and SXT
combination (1:19) (Sigma-Aldrich) [10,11].
Following the propagation procedure indicated by the manufacturer (ATCC, Manassas, VA, USA),
all strains were frozen in trypticase soy broth containing 10% glycerol and maintained at −80 ◦C until
revived and sub-cultured for testing. Inoculated plates were incubated for 18 to 24 h at 35 ◦C ± 1 ◦C
in 5% ± 2% CO2 and sub-cultured prior to use. The inoculum used in the primary and secondary
screen was prepared via the direct colony suspension method as described in the CLSI document Vet
01-A4 [10] and adjusted to 105 colony-forming units (CFU)/mL in cation-adjusted Mueller Hinton
broth (CA-MHB) supplemented with thymidine phosphorylase (TP) (200U/L).
The CA-MHB (Thermo Fisher Scientific, Waltham, MA, USA) was prepared as per the instructions
of the manufacturer and adjusted to pH 7.3± 0.1 prior to autoclaving [10]. After autoclaving, CA-MHB
was stored overnight at room temperature. TP (Becton, Dickinson and Company, Franklin Lakes, NJ,
USA) (200U/L) was added to CA-MHB prior to use in the HTS assay.
2.2. High-Throughput Screens
Bacterial growth inhibition was monitored by using the BacTiter-Glo™ microbial cell viability
(Thermo Fisher Scientific) fluorescence-based assay to quantify adenosine triphosphate content
in viable cells. Automation for high-throughput screening included assay reagent handling in
384-well format (Corning 3571; black flat bottom polystyrene tissue culture-treated sterile microplates),
compound addition (Multivolume ATS Acoustic Bravo Liquid Dispenser, Atlantic Lab Equipment,
Salem, MA, USA), inoculated media and BactTiter Glo addition (Multidrop Combi Reagent Dispenser,
Thermo Fisher Scientific), and assay monitoring (Envision luminometer, Perkin Elmer, Waltham,
MA, USA).
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All robotic liquid handling, compound transfer, and plate reading were performed at Zoetis
Global Therapeutics Research (Kalamazoo, MI, USA). Positive (high-percent effect (HPE)) (n = 16) and
negative control (zero-percent effect (ZPE)) (n = 16) wells were added to each tested plate. High-percent
effect controls consisted of 100 µg/mL of SXT (1:19 ) in dimethyl sulfoxide (DMSO), and ZPE controls
consisted of DMSO only. Test compounds (0.3 µL of either compound, HPE or ZPE) were first added
to each well in the plates followed by the inoculated media (30 µL containing 105 CFU/mL). After
16 to 20 h of incubation at 35 ◦C ± 1 ◦C in 5% ± 2% CO2, the BactiterGlo reagent (30 µL) was added.
Plates were covered with a low-evaporation lid seal, and contents were briefly mixed (2 min) on an
orbital shaker (Standard Analog 1000 Orbital Shaker, Troemner™, Thermo Fisher Scientific) to induce
cell lysis. Fluorescence (Envision luminometer, Perkin Elmer) was read after 20–40 min of incubation
at room temperature.
In the primary screen, a library of 7884 compounds was screened in a 384-well plate setting against
E. coli ATCC 25922. The library of compounds included a collection of Food and Drug Administration
(FDA)-approved molecules, as well as synthetic small molecules, natural products, known bioactives,
peptides, peptidomimetics, inorganic and metal-containing products sourced from Zoetis Global
Therapeutics Research. Test compounds from the screening library were added to the reaction at a final
concentration of 10 µg/mL in 0.99% DMSO. The secondary screen consisted of an 11-point titration
(3.16 × dilution) of inhibitory compounds from the primary screen. Tested concentrations were 100,
31.65, 10.02, 3.17, 1, 0.32, 0.1, 0.03, 0.01, 0.003, and 0.001 µg/mL. A concentration of 100 µg/mL of SXT
was used as both HPE and as a positive control. Two different titrations for SXT were tested on each
run (n = 3) of the secondary screen. The primary screen was run in duplicates (N1 and N2), and the
secondary screen was run in triplicates (N1, N2 and N3) on different days.
The PubChem Sketcher V2.4 online software (PubChem, National Center of Biotechnology
Information, Bethesda, MD, USA) was used to draw the NSC319726 lead structure. Microsoft excel
(Microsoft corporation, Redmond, Washington, USA), Tibco Spotfire (Tibco software Inc., Palo Alto,
CA, USA), and GraphPad Prism v. 6.0 (GraphPad Software, La Jolla, CA, USA) software were used for
data analysis. Briefly, dose–response curves and calculation of half maximal inhibitory concentration
(IC50) (µg/mL) and pIC50 data (N1, N2 and N3) were made using Excel tools and GraphPad Prism
software, v. 6.0. Briefly, individual concentration–effect curves were generated in GraphPad Prism by
plotting the logarithm of the tested concentration for each of the different tested compounds (X) versus
the corresponding percent inhibition values (Y) using least square (ordinary) fit. GraphPad Prism
reports both the best fit IC50 and its log. The best fit IC50 values were calculated in GraphPad Prism
using log (inhibitor) versus response-variable slope (four parameters) equation, where Y = Bottom
+ (Top − Bottom)/(1 + 10((LogIC50 − X)∗HillSlope)). IC50 data were converted to M from µg/mL in Excel
as follows: IC50 (M) = IC50 (µg/mL)/(1000 ∗ MW), where MW is the molecular weight expressed in
g/mol. pIC50 were calculated in excel as follows: pIC50 = −log [IC50 (M)]. Bland–Altman plots were
drawn using Excel and Tibco Spotfire software.
3. Results
The strain E. coli ATCC 25922 used in the primary screen was susceptible to SMX, SXT (1:19),
and TMP (Table 1) [10,11]. Data of duplicate primary screens run on separate days (N1 and N2) were
of high quality, with Z-prime statistical scores of 0.65 (N1) and 0.61 (N2), both > 0.5, indicative of an
excellent assay, exhibiting a large separation band between HPE and ZPE (fold window = ZPE/HPE ~
13 and ~ 32 for N1 and N2, respectively), good signal-to-noise ratios, and good signal-to-background
ratios in the compound and control wells [12]. This was consistent with signal window (SW) values
(6.11 (N1) and 4.91 (N2)) that were large enough and >2, indicative of a recommended assay [13].
All data were reported as percent effect of inhibition relative to the average of the ZPE and HPE
(percent effect of inhibition = (sample luminescence−average ZPE)/(average HPE−average ZPE) ∗
100)). Active molecules were identified as those showing more than 50% percent effect of inhibition.
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Using this threshold, 112 compounds were found to inhibit the growth of E. coli ATCC 25922, giving a
primary hit rate of 1.42% over the entire screen.
Table 1. IC50 (µg/mL) and pIC50 data (N1, N2, and N3) for two titrations of SXT (SXT_1 and SXT_2)
on each run (N1, N2, and N3) of the secondary screen and their corresponding average, standard
deviation, sample size, confidence coefficient for 95%CI, margin of error, CI upper bound, CI lower
bound, maximum (sample), minimum (sample), and range (sample and CI).
Escherichia coli ATCC 25922
SXT (MW 633.68 g/mol) IC50 (µM) pIC50
SXT_1_N1 0.042 4.38
SXT_1_N2 0.017 4.773
SXT_1_N3 0.016 4.807
SXT_2_N1 3.29 × 10−6 8.483
SXT_2_N2 0.014 4.84
SXT_2_N3 0.003 5.587
Average 0.015 5.478
Standard deviation 1.523
Sample size 6
Confidence coefficient, for 95% CI 1.96
Margin of error 1.219
CI Upper bound 6.697
CI Lower bound 4.26
Maximum (sample) 8.483
Minimum (sample) 4.38
Range (sample) 4.103
Range (CI) 2.438
SXT: trimethoprim/sulfamethoxazole; CI: confidence interval; IC50:half maximal inhibitory concentration;
pIC50: log (IC50).
In the secondary screen, IC50 determinations were performed for the 112 active compounds from
the primary screen. The secondary screen was run against each of E. coli ATCC 25922, E. coli ATCC
86980, E. coli ATCC 29181, and E. coli AHDRCC 81113, separately. Similarly to the primary screen,
Z-prime statistical scores were > 0.5 (0.67 for N1, 0.72 for N2, and 0.68 for N3), and SW values > 2 (7.21
for N1, 8.46 for N2 and 7.51 for N3) [12,13].
Generally, a good agreement in Bland–Altman plots was observed in the IC50 values obtained
from the three different secondary assay runs (N1, N2, and N3) for each strain (Figure S1, supplemental
data) [14–18]. The Bland–Altman plot shows that the average differences in pIC50 are zero or very close
to zero, indicating no significant bias between replicate assays (N1, N2, and N3) in each of the different
tested strain [14–18]. Moreover, there were no trends in the data, and variability was reasonably
uniform across the range of potency (artifacts, temporal and spatial plate effect) [14–18]. The limits of
agreement (LoA) and minimum significant difference (MSD) were acceptable. Any positive outside the
95% confidence interval of the LoA and/or MSD interval was considered an outlier and was excluded
from data analysis. The number of those outliers was very low (1.34%). Most outliers were seen
among resistant strains (marked with numbers in Figure S1, supplemental data) and corresponded to
nuisance hits.
In HTS lead discovery, pIC50 ≥ 6 corresponds to a positive and a potent inhibitor. However,
in antimicrobial lead discovery, pIC50 ≥ 4 corresponds to a positive. The lower bound threshold at 95%
CI of pIC50 calculated on the basis of data of the two different titrations of the positive control (SXT)
(n = 6) was used as cut-off to determine hits during data analysis (pIC50 ≥ 4.26). For compounds where
4 < pIC50 < 4.26, pIC50 (N1, N2, and N3), values were averaged, and compounds were considered
as hits if the average pIC50 ≥ 4.26 (Table 1). Additional criteria such as the overall appearance of
the curve, <60% effect, high IC50, toxicity and safety issues were considered in the selection of hits.
On the basis of these criteria, NSC319726 (Figure 1) was identified as a potential antimicrobial lead,
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effective against the tested susceptible and multidrug-resistant E. coli strains (IC50 averages ranging
from 0.0021 to 0.0232 µM among the tested strains) (Table 2).Bio olecules 2018, 8, x FOR PEER REVIEW  5 of 8 
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Table 2. Average IC50 ± standard deviation (SD) (µg/mL and µM) and average pIC50 ± SD for
NSC319726. Averages IC50 and SD were calculated on the basis of N1, N2, and N3 data of the
secondary screen for all strains and tested compounds.
Strain Average IC50 ± SD (µg/mL) Average IC50 ± SD (µM) Average pIC50 ± SD
E. coli ATCC 25922 0.774 ± 0.394 0.0033 ± 0.002 5.524 ± 0.245
E. coli ATCC 86980 0.481 ± 0.027 0.0021 ± 0.0001 5.688 ± 0.025
E. coli ATCC 29181 3.071 ± 0.285 0.0131 ± 0. 01 4.884 ± 0.041
E. coli AHDRCC 81113 5.432 ± 2.731 0.0232 ± 0.012 4.668 ± 0.201
Susceptibility results (n = 2) by the broth microdilution procedure [10] for NSC319726 with
E. coli strains susceptible (E. coli ATCC 25922) and resistant (E. coli AHDRCC 81113) to antifolates
showed that NSC319726 inhibited the growth of both antifolate-susceptible and -resistant strains
(Table 3). This finding was consistent with the generated IC50 data (Table 2). The NSC319726
exhibited moderate MICs (128 µg/mL ± two-fold dilution) against both E. coli ATCC 25922 and
E. coli AHDRCC 81113. The potency of NSC319726 was comparable in both antifolate-susceptible
and -resistant E. coli strains tested. The potency of NSC319726 was also comparable to that of SMX
alone against the antifolate-susceptible strain (E. coli ATCC 25922), with the consideration of one
two-fold dilution difference in potency between SMX and NSC319726. Notably, E. coli AHDRCC 81113
is multidrug-resistant as it is resistant to antifolates (SMX, TMP, and SXT) and to ampicillin, florfenicol,
penicillin, and tilmicosin. While SMX alone is ineffective against E. coli AHDRCC 81113, NSC319726
inhibited its growth with a MIC of 128 µg/mL (Table 3).
Table 3. Recorded MICs (µg/mL) for TMP, SMX, SXT, and NSC319726 against E. coli ATCC 25922 and
E. coli AHDRCC 81113 (n = 2).
Susceptibility Profile MIC (µg/mL)
TMP SMX SXT (1:19) NSC319726
E. coli ATCC 25922 S to SMX, TMP, and SXT
0.0005 64 0.12/2.4 128
0.0005 64 0.06/1.2 256
E. coli AHDRCC 81113 R to SMX, TMP, and SXT
1024 >2048 >32/608 128
1024 >2048 >32/608 128
MIC: minimum inhibitory concentration; R: resistant; S: susceptible; SMX: sulfamethoxazole; TMP: trimethoprim.
4. Discussion
In our search for novel antifolates, NSC319726 exhibited antimicrobial activity against the
susceptible and multidrug-resistant E. coli strains tested (resistance to ampicillin, florfenicol, kanamycin,
penicillin, streptomycin, SMZ, SXT, tilmicosin, and TMP) (Table 2). Considering the HTS data,
the thiosemicarbazone NSC319726 was a potent inhibitor of all the tested strains (pIC50 values ≥ 4.26)
(Table 2). Considering the MIC data, NSC319726 demonstrated adequate activity against the tested
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strains (MIC = 128 µg/mL± two-fold dilution), warranting further investigation. NSC319726 inhibited
the growth of multidrug-resistant E. coli strains and is highlighted as a novel template serving as a
potential antimicrobial lead.
Previously, NSC319726 was reported to inhibit the growth of mammalian cancer cell lines with
a p53 mutation and to inhibit the growth of pathogenic fungi [19]. Here, we report for the first time
NSC319726 as a potent inhibitor against multidrug-resistant E. coli strains (Table 2). The antifungal
effect of NSC319726 against Candida albicans SC5314 is due to downregulation of ribosome biogenesis
and protein synthesis [20]. On the basis of the antifungal data, we assume that the antimicrobial
activity of NSC319726 is likely due to inhibition of protein synthesis through an interaction with
the bacterial ribosome. On the basis of pIC50 values (≥4.26), NSC319726 is a more potent inhibitor
than SXT in all the tested E. coli strains (Table 2). It is more potent against antifolate-susceptible
E. coli ATCC 25922 (IC50 = 0.0033 µM) and SMX-resistant E. coli ATCC 86980 (IC50 = 0.0021 µM)
than against E. coli ATCC 29181 resistant to TMP (IC50 = 0.0131 µM) and E. coli AHDRCC 81113
resistant to TMP, SMX, and SXT (IC50 = 0.0232 µM) (Table 2). Overall, the IC50 values (Table 2)
indicate that the antimicrobial activity of NSC319726 against E. coli is similar to that previously
observed against pathogenic fungi, including Candida species, Aspergillus fumigatus, and Cryptococcus
neoformans [20]. Considering that the highest growth inhibition IC50 value obtained with NSC319726
against multidrug-resistant E. coli does not exceed by more than 2.7 times the highest growth inhibition
IC50 value obtained with NSC319726 against pathogenic fungi, the cytotoxic IC50/growth inhibition
IC50 data can be extrapolated (by dividing by 2.7, corresponding to the highest fold difference in
IC50 growth inhibition between the two studies [20]) from the study conducted by Sun et al. [20] and
is ~296-fold higher following a 24 h incubation of cell lines with NSC319726 and ~13- and 122-fold
higher at 48 and 72 h (The toxicity of NSC319726 to human liver cell lines was expressed as ratios
of IC50/MIC50 by Sun et al. Depending upon the time of incubation with the compound, their IC50
concentrations were 35-, 330-, and 825-fold higher to achieve inhibition than the concentration to
achieve an MIC50, 72, 48, and 24 h post-treatment, respectively [20]). Despite this drop in fold difference,
it remains considerably high, indicating limited toxicity at the tested concentrations. Since previously
published cytotoxicity data indicate no significant toxicity of the compound to human and rodent
cell lines, [20] NSC319726 constitutes an attractive lead compound with strong antimicrobial activity
against multidrug-resistant E. coli. It is a good candidate for analoguing programs aiming to enhance
its antimicrobial activity and reduce its cytotoxicity.
The challenge presented by the NSC319726 lead is the lack of any pre-existing information
about its characteristics and its biological behaviour. Nonetheless, this hurdle can be easily overcome
through the synthesis and evaluation of NSC319726 analogues. The synthesis of analogues will help
understand the precise mechanism of action of the lead pharmacophore, define structure–activity
relationship requirements, and reveal the impact of the various structural features on the antibacterial
activity, toxicity, physicochemical properties, and pharmacokinetic parameters. The recorded MIC
of NSC319726 against resistant strains (128 µg/mL) is the most crucial requirement used to guide
such analoguing programs and structure activity relationship (SAR) studies. The SAR efforts would
then have clearly defined biological goals including in vitro and in vivo activity, toxicity, as well
as physicochemical properties and pharmacokinetic parameters. An NSC319726 analogue which
succeeds in meeting the in vitro and then the in vivo criteria, passes toxicological profiling, and meets
the PK requirements would then move forward the antimicrobial discovery pipeline, become a clinical
drug candidate suitable for additional preclinical development, and ultimately enter Phase I human
clinical trials. This is not an uncommon practice in drug discovery. In fact, linezolid, the first clinically
useful oxazolidinone, portrays a good example of a successful antimicrobial that emerged from an
analoguing program of the novel oxazolidinone antimicrobial class that had unknown characteristics
and biological behaviour at the time [21]. The synthesis of NSC319726 analogues is straightforward
and could be initiated from ketone and hydrazine. Chemical modifications will probe a number of
structural features of the NSC319726 lead compound to assess their impact on antibacterial activity
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and toxicity. Chemical modifications can include the replacement of the pyridine with different
heterocycles, the addition/modification of different alkyl chains and aromatic groups, the replacement
of sulfur with oxygenation, the addition of other nitrogen ring systems, the addition of positive
charges, and the addition of negative charges. After understanding the SAR structural constraints and
mechanism of action, unnecessary structures can be eliminated. Following the confirmation of in vitro
activity, should in vivo issues such as toxicity and physicochemical issues such as solubility arise, a
prodrug structure can be synthesized. Finally, since peptides are easier to synthesize, are presented
with better clearance, and have a less toxic profile than small organic compounds, the new lead
structure can be converted into a non-standard dipeptide. The advantage of attempting to synthesize a
non-standard dipeptide structure over a traditional dipeptide structure is the possibility of a longer
half-life, which may further decrease the administered dose and toxicity.
5. Conclusions
The NSC319726 compound constitutes a potential antimicrobial lead serving as a novel template.
NSC319726 exhibits a good antimicrobial activity against E. coli, irrespective of concomitant resistance
to antifolates and to other antimicrobial classes. The thiosemicarbazone NSC319726 is suitable for a
medicinal chemistry program aiming to develop novel analogues with enhanced antimicrobial activity
and reduced toxicity. More in vitro and in vivo efficacy, toxicological, and pharmacokinetic studies
are required to deem if NSC319726 pharmacophore will continue to serve as a lead antimicrobial and
move forward as a pre-clinical candidate.
Supplementary Materials: The following are available online at http://www.mdpi.com/2218-273X/8/4/166/s1,
Figure S1: Bland–Altman plots of pairwise comparison of the potencies of the positive compounds determined in
different assay runs (N1, N2, and N3) of the secondary screen in each of the tested strains (E. coli ATCC 25922,
E. coli ATCC 86980, E. coli ATCC 29181, and E. coli AHDRCC 81113, respectively.
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